ABL Bio Inc (298380) — Cash Flow-to-Debt Ratio
ABL Bio Inc (298380) has a Cash Flow-to-Debt Ratio of -0.19x as of December 2025, meaning its operating cash flow of ₩-23.62 Billion could theoretically repay 0% of its total liabilities (₩124.24 Billion) in one year. See ABL Bio Inc (298380) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ABL Bio Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for ABL Bio Inc across 10 annual periods. Also explore ABL Bio Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for ABL Bio Inc (2016–2025)
Year-by-year debt coverage analysis for ABL Bio Inc. For market capitalisation and broader financial context, see ABL Bio Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.33x | ₩-41.25 Billion | ₩124.24 Billion | ▲ +69.0% |
| 2024 | -1.07x | ₩-69.40 Billion | ₩64.70 Billion | ▼ -225.5% |
| 2023 | -0.33x | ₩-28.36 Billion | ₩86.07 Billion | ▼ -152.8% |
| 2022 | 0.62x | ₩72.13 Billion | ₩115.67 Billion | ▲ +114.6% |
| 2021 | -4.27x | ₩-40.61 Billion | ₩9.50 Billion | ▲ +16.6% |
| 2020 | -5.12x | ₩-47.29 Billion | ₩9.23 Billion | ▼ -134.0% |
| 2019 | -2.19x | ₩-23.86 Billion | ₩10.89 Billion | ▼ -105.8% |
| 2018 | -1.06x | ₩-12.67 Billion | ₩11.91 Billion | ▼ -1483.8% |
| 2017 | -0.07x | ₩-7.14 Billion | ₩106.32 Billion | ▲ +57.7% |
| 2016 | -0.16x | ₩-3.12 Billion | ₩19.63 Billion | — |